| Literature DB >> 27514465 |
Rif S El-Mallakh1, R Jeannie Roberts2, Peggy L El-Mallakh3, Lillian Jan Findlay3, Kristen K Reynolds4.
Abstract
Pharmacogenomic testing in psychiatry is becoming an established clinical procedure. Several vendors provide clinical interpretation of combinatorial pharmacogenomic testing of gene variants that have documented predictive implications regarding either pharmacologic response or adverse effects in depression and other psychiatric conditions. Such gene profiles have demonstrated improvements in outcome in depression, and reduction of cost of care of patients with inadequate clinical response. Additionally, several new gene variants are being studied to predict specific response in individuals. Many of these genes have demonstrated a role in the pathophysiology of depression or specific depressive symptoms. This article reviews the current state-of-the-art application of psychiatric pharmacogenomics.Entities:
Keywords: 2D6; Antidepressants; Antipsychotics; CYP2D6; OPRM1; Pharmacogenomic testing; Psychiatric pharmacogenomics; SLC6A4
Mesh:
Year: 2016 PMID: 27514465 DOI: 10.1016/j.cll.2016.05.001
Source DB: PubMed Journal: Clin Lab Med ISSN: 0272-2712 Impact factor: 1.935